Values First Advisors Inc. Has $278,000 Stake in Boston Scientific Co. (NYSE:BSX)

Values First Advisors Inc. lifted its stake in Boston Scientific Co. (NYSE:BSX) by 817.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,110 shares of the medical equipment provider’s stock after purchasing an additional 2,771 shares during the quarter. Values First Advisors Inc.’s holdings in Boston Scientific were worth $278,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Certuity LLC grew its stake in Boston Scientific by 26.3% in the fourth quarter. Certuity LLC now owns 3,885 shares of the medical equipment provider’s stock valued at $347,000 after purchasing an additional 809 shares in the last quarter. Schear Investment Advisers LLC raised its stake in shares of Boston Scientific by 16.9% during the 4th quarter. Schear Investment Advisers LLC now owns 23,106 shares of the medical equipment provider’s stock worth $2,064,000 after purchasing an additional 3,336 shares in the last quarter. Portfolio Design Labs LLC acquired a new stake in shares of Boston Scientific during the 4th quarter valued at about $975,000. Quent Capital LLC grew its stake in shares of Boston Scientific by 29.6% in the 4th quarter. Quent Capital LLC now owns 3,256 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 744 shares in the last quarter. Finally, Essex Financial Services Inc. increased its holdings in Boston Scientific by 13.1% in the fourth quarter. Essex Financial Services Inc. now owns 2,621 shares of the medical equipment provider’s stock worth $234,000 after buying an additional 303 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 0.2 %

BSX opened at $105.80 on Thursday. Boston Scientific Co. has a fifty-two week low of $64.54 and a fifty-two week high of $107.17. The company has a market capitalization of $155.93 billion, a P/E ratio of 84.64, a P/E/G ratio of 2.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm’s fifty day moving average price is $95.50 and its two-hundred day moving average price is $87.72.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. On average, analysts anticipate that Boston Scientific Co. will post 2.83 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BSX. Canaccord Genuity Group increased their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Royal Bank of Canada increased their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a report on Thursday, February 6th. Bank of America increased their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Finally, Citigroup boosted their target price on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $107.39.

Insider Transactions at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the sale, the executive vice president now owns 29,308 shares of the company’s stock, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company’s stock, valued at $87,306.06. This trade represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,830 shares of company stock valued at $6,415,729. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.